Year archive

Hutchmed (China) Limited — 2021 filings

All 149 regulatory filings released by Hutchmed (China) Limited (HCM) in 2021, sourced directly from the official regulator.

149 Filings

2021 Period

2021 filings (149)

Filing	Released	Lang
Blocklisting Six Monthly Return Regulatory Filings	2021-12-31	English
Total Voting Rights Regulatory Filings	2021-12-31	English
6-K Foreign Filer Report	2021-12-20	English
HUTCHMED Included in FTSE Russell Indexes Regulatory Filings	2021-12-20	English
6-K Foreign Filer Report	2021-12-15	English
Grant of Share Options and Awards under LTIP Regulatory Filings	2021-12-15	English
6-K Foreign Filer Report	2021-12-14	English
HMPL-523 Clinical Data Presented at ASH Regulatory Filings	2021-12-14	English
6-K Foreign Filer Report	2021-12-10	English
HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21 Regulatory Filings	2021-12-10	English
6-K Foreign Filer Report	2021-12-06	English
HUTCHMED Completes Planned Enrollment of FRESCO-2 Regulatory Filings	2021-12-06	English
6-K Foreign Filer Report	2021-12-03	English
Updated NRDL to include ELUNATE and SULANDA Regulatory Filings	2021-12-03	English
6-K Foreign Filer Report	2021-11-30	English
Total Voting Rights Regulatory Filings	2021-11-30	English
6-K Foreign Filer Report	2021-11-24	English
HUTCHMED and AZ Initiate SACHI Phase 3 Trial Regulatory Filings	2021-11-24	English
6-K Foreign Filer Report	2021-11-08	English
HUTCHMED to Present Clinical Data at ASH Regulatory Filings	2021-11-08	English
6-K Foreign Filer Report	2021-11-01	English
HUTCHMED and AZ Initiate SAMETA Global P3 Trial Regulatory Filings	2021-11-01	English
6-K Foreign Filer Report	2021-10-29	English
Total Voting Rights Regulatory Filings	2021-10-29	English
6-K Foreign Filer Report	2021-10-28	English
HUTCHMED Initiates Phase III Trial of HMPL-523 Regulatory Filings	2021-10-28	English
6-K Foreign Filer Report	2021-10-20	English
Grant of Awards under Long Term Incentive Plan Regulatory Filings	2021-10-20	English
6-K Foreign Filer Report	2021-09-30	English
Total Voting Rights Regulatory Filings	2021-09-30	English
6-K Foreign Filer Report	2021-09-29	English
Closure of Non-Core OTC Joint Venture Divestment Regulatory Filings	2021-09-29	English
HUTCHMED Highlights Presentations at CSCO 2021 Regulatory Filings	2021-09-29	English
6-K Foreign Filer Report	2021-09-21	English
HUTCHMED Initiates Phase III Trial SURTORI-01 Regulatory Filings	2021-09-21	English
6-K Foreign Filer Report	2021-09-20	English
Japan Bridging Study For Surufatinib Initiated Regulatory Filings	2021-09-20	English
6-K Foreign Filer Report	2021-09-13	English
Breakthrough Therapy Designation for Amdizalisib Regulatory Filings	2021-09-13	English
6-K Foreign Filer Report	2021-09-08	English
HUTCHMED and AZ Initiate Phase III Trial in China Regulatory Filings	2021-09-08	English
6-K Foreign Filer Report	2021-09-07	English
HUTCHMED to Present Clinical Data at ESMO Regulatory Filings	2021-09-07	English
HUTCHMED Shares Included in Stock Connect Programs Regulatory Filings	2021-09-06	English
6-K Foreign Filer Report	2021-09-02	English
Grant of Share Options, and Awards under LTIP Regulatory Filings	2021-09-02	English
6-K Foreign Filer Report	2021-08-31	English
Total Voting Rights Regulatory Filings	2021-08-31	English
6-K Foreign Filer Report	2021-08-26	English
Phase Ib/II Trial of Fruquintinib & Tislelizumab Regulatory Filings	2021-08-26	English
6-K Foreign Filer Report	2021-08-23	English
HUTCHMED Selected for Certain Hang Seng Indexes Regulatory Filings	2021-08-23	English
ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION Regulatory Filings	2021-08-17	English
SC 13D Major Shareholding Notification	2021-08-16	English
6-K Foreign Filer Report	2021-08-09	English
HUTCHMED & Epizyme Announce TAZVERIK Collaboration Regulatory Filings	2021-08-09	English
6-K Foreign Filer Report	2021-07-30	English
Total Voting Rights Regulatory Filings	2021-07-30	English
FORM 6-K Foreign Filer Report	2021-07-28	English
Interim Results and Business Updates Interim / Quarterly Report H1 2021	2021-07-28	English
6-K Foreign Filer Report	2021-07-28	English
Phase II Trial of ORPATHYS Initiated Regulatory Filings	2021-07-28	English
FORM 6-K Foreign Filer Report	2021-07-23	English
Stabilizing Actions & End of Stabilization Period Regulatory Filings	2021-07-23	English
6-K Foreign Filer Report	2021-07-16	English
Holding(s) in Company Major Shareholding Notification	2021-07-16	English
Surufatinib MAA Submitted and Validated by the EMA Regulatory Filings	2021-07-16	English
6-K Foreign Filer Report	2021-07-14	English
Holding(s) in Company Major Shareholding Notification	2021-07-14	English
6-K Foreign Filer Report	2021-07-13	English
First Commercial Sale of ORPATHYS® in China Regulatory Filings	2021-07-13	English
FORM 6-K Foreign Filer Report	2021-07-12	English
Full Exercise of the Over-allotment Option Share Issue/Capital Change	2021-07-12	English
6-K Foreign Filer Report	2021-07-06	English
HUTCHMED Initiates Phase I Trials of HMPL-295 Regulatory Filings	2021-07-06	English
6-K Foreign Filer Report	2021-07-02	English
Holding(s) in Company Major Shareholding Notification	2021-07-02	English
Notice of Results Report Publication Announcement	2021-07-02	English
US FDA Accepts NDA Filing for Surufatinib Regulatory Filings	2021-07-01	English
AMENDMENT NO. 1 Major Shareholding Notification	2021-07-01	English
SC 13D/A Major Shareholding Notification	2021-06-30	English
FORM 6-K Foreign Filer Report	2021-06-30	English
Holdings in Company Major Shareholding Notification	2021-06-30	English
Total Voting Rights Regulatory Filings	2021-06-30	English
Closing of Global Offering and Hong Kong Listing Share Issue/Capital Change	2021-06-30	English
6-K Foreign Filer Report	2021-06-29	English
Blocklisting Six Monthly Return Regulatory Filings	2021-06-29	English
FORM 6-K Foreign Filer Report	2021-06-24	English
424B5 Prospectus	2021-06-24	English
6-K Foreign Filer Report	2021-06-24	English
FORM 6-K Foreign Filer Report	2021-06-23	English
HUTCHMED Announces Pricing of Global Offering Share Issue/Capital Change	2021-06-23	English
Savolitinib approved in China for lung cancer Regulatory Filings	2021-06-22	English
FORM 6-K Foreign Filer Report	2021-06-21	English
FORM 6-K Foreign Filer Report	2021-06-21	English
FORM 6-K Foreign Filer Report	2021-06-21	English
424B5 Prospectus	2021-06-21	English
FORM 6-K Foreign Filer Report	2021-06-21	English
6-K Foreign Filer Report	2021-06-21	English
HUTCHMED Announces NMPA Approval of Surufatinib Regulatory Filings	2021-06-18	English
HUTCHMED Launches Hong Kong IPO Share Issue/Capital Change	2021-06-18	English
Disclosure Update Regulatory Filings	2021-06-18	English
6-K Foreign Filer Report	2021-05-20	English
Clinical Data to be Presented at ASCO21 Regulatory Filings	2021-05-20	English
6-K Foreign Filer Report	2021-05-17	English
HUTCHMED to Host Company Update Regulatory Filings	2021-05-17	English
Prospectus 2021 Prospectus	2021-05-14	English
6-K Foreign Filer Report	2021-05-07	English
HUTCHMED to Attend Upcoming Investor Conferences Regulatory Filings	2021-05-07	English
6-K Foreign Filer Report	2021-05-04	English
Change of Company Name Regulatory Filings	2021-05-04	English
Surufatinib FDA Rolling NDA Submission Completed Regulatory Filings	2021-05-04	English
Second Price Monitoring Extn Regulatory Filings	2021-04-30	English
Price Monitoring Extension Regulatory Filings	2021-04-30	English
6-K Foreign Filer Report	2021-04-29	English
Phase II Registration Study of HMPL-689 Initiated Regulatory Filings	2021-04-29	English
6-K Foreign Filer Report	2021-04-28	English
Result of AGM Declaration of Voting Results & Voting Rights Announcements	2021-04-28	English
6-K Foreign Filer Report	2021-04-23	English
Vesting of awards under Long Term Incentive Plan Director's Dealing	2021-04-23	English
6-K Foreign Filer Report	2021-04-14	English
Notification of Dilution of Voting Rights Major Shareholding Notification	2021-04-14	English
SC 13D/A Major Shareholding Notification	2021-04-13	English
6-K Foreign Filer Report	2021-04-08	English
$100m Investment by Baring Private Equity Asia Capital/Financing Update	2021-04-08	English
6-K Foreign Filer Report	2021-03-31	English
Total Voting Rights Regulatory Filings	2021-03-31	English
6-K Foreign Filer Report	2021-03-29	English
Grant of LTIP Awards and Share Options Director's Dealing	2021-03-29	English
Initiates International Phase I Trials of HMPL-306 Regulatory Filings	2021-03-29	English
6-K Foreign Filer Report	2021-03-26	English
Annual Financial Report Report Publication Announcement	2021-03-26	English
6-K Foreign Filer Report	2021-03-24	English
Agreement to Divest Non-Core OTC Joint Venture Regulatory Filings	2021-03-24	English
6-K Foreign Filer Report	2021-03-24	English
Phase Ib/II Trial of Surufatinib with Tislelizumab Regulatory Filings	2021-03-24	English
6-K Foreign Filer Report	2021-03-10	English
Vesting of awards under Long Term Incentive Plan Director's Dealing	2021-03-10	English
Publication of Form 20-F Report Publication Announcement	2021-03-04	English
6-K Foreign Filer Report	2021-03-04	English
FORM 20-F Annual Report FY 2020	2021-03-04	English
Final Results, Business Update and Name Change Earnings Release FY 2020	2021-03-04	English
SEC SCHEDULE 13G Major Shareholding Notification	2021-02-16	English
6-K Foreign Filer Report	2021-02-03	English
Notice of Results Report Publication Announcement	2021-02-03	English
6-K Foreign Filer Report	2021-01-14	English
Savolitinib Data to be Presented at Virtual WCLC Regulatory Filings	2021-01-14	English
6-K Foreign Filer Report	2021-01-11	English
Chi-Med & Inmagene Announce Strategic Partnership Regulatory Filings	2021-01-11	English

Filings by year

2026 30 filings
2025 104 filings
2024 105 filings
2023 108 filings
2022 96 filings
2021 149 filings
2020 122 filings
2019 71 filings
2018 77 filings
2017 88 filings
2016 81 filings
2015 53 filings
2014 28 filings
2013 23 filings